Related Experiment Video
Updated: Jul 26, 2025

Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
Published on: May 7, 2019
Mesangiolysis in Pathological Chronic Active Antibody-Mediated Rejection in Kidney Transplant Biopsies
Yuki Suto1, Hideyo Oguchi1, Naobumi Tochigi2
1Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan.
Introduction:
This study aimed to determine if immune or nonimmune and acute or chronic lesions associated with mesangiolysis (MGLS) occurred in biopsy-proven pathological chronic active antibody-mediated rejection (P-CAABMR) in kidney transplant biopsies.
Methods:
We evaluated MGLS in 41 patients with biopsy findings of P-CAABMR from January 2016 to December 2019. Histological scoring was evaluated by Banff classification. Multivariate logistic regression analysis was performed using a forward selection method.
Results:
Fifteen of the 41 P-CAABMR biopsies (36.6%) cases showed MGLS. The estimated glomerular filtration rate (eGFR) was significantly lower in the MGLS-positive compared with the MGLS-negative group, and proteinuria was significantly higher in the MGLS-positive compared with the MGLS-negative group. In the clinical model, multivariate analysis was performed using covariates of eGFR and duration after transplantation significantly correlated with MGLS by simple analysis, in addition to type of calcineurin inhibitor use (tacrolimus or cyclosporine), donor-specific antibodies, diabetes, and hypertension grade defined by use of antihypertensive therapy or/and blood pressure level. Only hypertension grade was significantly correlated with MGLS. In the pathological model, multivariate analysis was performed using the presence of FSGS and the aah and cg scores significantly correlated with MGLS by simple analysis, in addition to g and ptc scores. The cg score was significantly correlated with hypertension grade, duration after transplantation, g, ah, and aah.
Conclusion:
Lower graft function and higher proteinuria was observed in MGLS of P-CAABMR. The Banff cg score was independently related to MGLS in multivariate analysis. Sustained glomerulitis, calcineurin inhibitor nephrotoxicity, and hypertension may cause Banff cg lesions, leading to MGLS in P-CAABMR.
Insights
Mesangiolysis (MGLS) lesions were found in 36.6% of kidney transplant biopsies with chronic active antibody-mediated rejection (CAABMR). These MGLS cases showed poorer kidney function and higher proteinuria, linked to hypertension and specific Banff scores.
Area of Science:
- Nephrology
- Transplant Immunology
- Pathology
Background:
- Kidney transplant rejection is a significant clinical challenge.
- Antibody-mediated rejection (AMR) is a major cause of graft loss.
- Mesangiolysis (MGLS) is a histological finding that may indicate specific pathological processes.
Purpose of the Study:
- To investigate the occurrence and clinical significance of mesangiolysis (MGLS) in kidney transplant recipients with biopsy-proven pathological chronic active antibody-mediated rejection (P-CAABMR).
- To identify clinical and pathological factors associated with MGLS in P-CAABMR.
Main Methods:
- Retrospective analysis of 41 kidney transplant biopsies with P-CAABMR.
- Histological evaluation using Banff classification criteria.
- Multivariate logistic regression analysis to identify associated factors.
Main Results:
- Mesangiolysis (MGLS) was identified in 36.6% of P-CAABMR cases.
- MGLS-positive cases exhibited significantly lower estimated glomerular filtration rate (eGFR) and higher proteinuria.
- Hypertension grade and Banff cg score were significantly correlated with MGLS in multivariate analysis.
Conclusions:
- Mesangiolysis (MGLS) is present in a significant subset of P-CAABMR cases and is associated with worse graft function.
- The Banff cg score is an independent predictor of MGLS in P-CAABMR.
- Hypertension, sustained glomerulitis, and calcineurin inhibitor nephrotoxicity may contribute to MGLS development in P-CAABMR.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction

